Follow us on LinkedIn
España
NTC
Novelty, Technology, Care
Lertal® significantly favors good functioning of the immune system
- Sept 03, 2019
Lertal® significantly favors good functioning of the immune system the immune system’s activity and improves the management of rhinoconjunctivitis in children.
NTC ACQUIRES FROM NMTECH UK TiAb AND SIAB BASED TECHNOLOGY
- June 12, 2019
Milan, Italy, June 12, 2019 – NTC focuses on strengthening its gynecology, dermatology and ophthalmology portfolio and pipeline.
NEW LIFE FOR PATIENTS SUFFERING FROM BLEPHARITIS: a controlled clinical study was presented on Blefastop, an ocular and periocular innovative therapeutic solution as adjuvant in blepharitis.
- June 5, 2019
Milan, June 5, 2019 – Recently, a controlled clinical study was presented on Blefastop, an ocular and periocular innovative therapeutic solution as adjuvant in blepharitis.
NTC grants further license and distribution rights to Santen for its fixed combination dexamethasone with levofloxacin in South East Asia
- May 22, 2019
Milan, Italy, May 22, 2019 – NTC Srl, R&D driven pharmaceutical company with headquarters in Italy, and Santen Pharmaceutical Co. Ltd, a global leader in ophthalmology, announce today the extension of their original agreement for Europe signed in December 2017.
PHARMACOVIGILANCE